C12N 1/36
Adaptation or attenuation of cells
C12N1/36 (Adaptation or attenuation of cells) appears on 399 US grants and 624 published applications in this corpus.
Search patents in C12N- Granted patents
- 399
- Published applications
- 624
- Assignees
- 375
- Inventors
- 1,274
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1978 | 1 | 0 |
| 1979 | 0 | 0 |
| 1980 | 0 | 0 |
| 1981 | 1 | 0 |
| 1982 | 2 | 0 |
| 1983 | 3 | 0 |
| 1984 | 2 | 0 |
| 1985 | 1 | 0 |
| 1986 | 0 | 0 |
| 1987 | 1 | 0 |
| 1988 | 2 | 0 |
| 1989 | 1 | 0 |
| 1990 | 0 | 0 |
| 1991 | 1 | 0 |
| 1992 | 2 | 0 |
| 1993 | 0 | 0 |
| 1994 | 1 | 0 |
| 1995 | 2 | 0 |
| 1996 | 3 | 0 |
| 1997 | 0 | 0 |
| 1998 | 2 | 0 |
| 1999 | 0 | 0 |
| 2000 | 1 | 0 |
| 2001 | 1 | 0 |
| 2002 | 2 | 2 |
| 2003 | 2 | 6 |
| 2004 | 3 | 6 |
| 2005 | 5 | 10 |
| 2006 | 2 | 11 |
| 2007 | 4 | 10 |
| 2008 | 4 | 10 |
| 2009 | 3 | 14 |
| 2010 | 8 | 30 |
| 2011 | 13 | 36 |
| 2012 | 18 | 43 |
| 2013 | 16 | 34 |
| 2014 | 26 | 39 |
| 2015 | 16 | 39 |
| 2016 | 32 | 36 |
| 2017 | 33 | 36 |
| 2018 | 19 | 26 |
| 2019 | 31 | 33 |
| 2020 | 27 | 36 |
| 2021 | 26 | 43 |
| 2022 | 25 | 22 |
| 2023 | 18 | 35 |
| 2024 | 14 | 30 |
| 2025 | 11 | 21 |
| 2026 | 14 | 16 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Tumor-targeting Salmonella gallinarum strain and use thereof6 Oct 2026US 12,751,978 B2Industry Foundation of Chonnam National University
- Tumor immunotherapy composition based on antigen-presenting cells activated by attenuated listeria monocytogenes, preparation method therefor and application thereof11 Aug 2026US 12,702,681 B2Shanghai RoyalTech Med CO., Ltd
- Attenuated Salmonella gallinarum expressing FliC or FliC-hIL2 and uses thereof11 Aug 2026US 12,702,685 B2Odysseus Bio Co., Ltd.
- Live attenuated strain of Streptococcus pneumoniae and pharmaceutical compositions comprising a live attenuated strain of S. pneumoniae4 Aug 2026US 12,698,471 B2UCL Business PLC
- Live attenuated non-transmissible vaccines7 Jul 2026US 12,674,131 B2University of Maryland, Baltimore
- Bacterial type iv secretion systems, methods of use for in vivo dna delivery, and method of engineering8 Oct 2026US 2026/0308604 A1University of Kentucky Research Foundation
- Composition comprising biofilm forming bacillus17 Sep 2026US 2026/0271940 A1Chr. Hansen A/S
- Microbial methods for conversion of lignocellulosic hydrolysates using oleaginous yeast3 Sep 2026US 2026/0258346 A1Insempra GmbH
- System and method for continually growing high populations of active and adapted facultative anaerobes using organic wastes containing indigenous microbiology23 Jul 2026US 2026/0209685 A1Environmental Bioorganic Sciences Corporation
- Engineered Microbes Comprising Tumor Neoantigen Vectors for Cancer Immunotherapy18 Jun 2026US 2026/0166133 A1The Trustees of Columbia University in the City of New York
Most cited
By later US patents
- Rapid growing microorganisms for biotechnology applications61US 6,709,852 B1Invitrogen Corporation · 2004
- Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals59US 5,580,557 AIowa State University Research Foundation, Inc. · 1996
- Live bacterial vaccines for viral infection prophylaxis or treatment43US 8,440,207 B2Aviex Technologies LLC · 2013
- Combination bacteriolytic therapy for the treatment of tumors42US 7,344,710 B2The Johns Hopkins University · 2008
- Live bacterial vaccines resistant to carbon dioxide (CO2), acidic PH and/or osmolarity for viral infection prophylaxis or treatment42US 8,647,642 B2Aviex Technologies LLC · 2014